February 13, 2017 / 1:45 PM / 7 months ago

BRIEF-Teva board seeks new CEO with extensive pharma experience

Feb 13 (Reuters) - Teva Pharmaceutical Industries Ltd

* Teva chairman: board has begun search for new CEO with extensive pharmaceutical experience

* Teva interim CEO says “committed” to 2017 EPS target range, will cut costs if needed to achieve it

* Teva interim CEO: Copaxone 40 mg competition in February would cut 2017 revenue by $1-$1.3 billion, EPS by $0.75-$0.95

* Teva says majority of U.S. generic launches expected only in second half of 2017 Further company coverage: (Reporting by Tova Cohen)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below